Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Entacapone (sodium salt)

Catalog No: tcsc2022

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1047659-02-8

Formula:
$C_{14}H_{14}N_3NaO_5$

Pathway:
Neuronal Signaling;Metabolic Enzyme/Protease

Target:
COMT;COMT

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Observed Molecular Weight:
327.27

Product Description

Entacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor with IC50 of 151 nM for PD treatment.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

IC50 Value: 151 nM

Target: COMT

in vitro: Entacapone inhibits catechol-O-methyltransferase(COMT) with similar IC50 in different tissues including live, duodenum, kidney and lung, but entacapone is more active than tolcapone in those tissues. Entacapone (
in vivo: Levodopa/carbidopa/entacapone has been shown to improve the pharmacokinetic profile of levodopa and provide superior symptomatic control compared with conventional levodopa/dopa decarboxylase inhibitor therapy. We report four case histories describing clinical experience of using levodopa/carbidopa/entacapone 200/50/200 mg, one of the latest doses of this formulation, in a range of patients with Parkinson\'s disease. These cases illustrate that levodopa/carbidopa/entacapone 200/50/200 mg provides improvements in symptomatic control.

Clinical trial: The combination product carbidopa/levodopa/entacapone (CLE) was approved in 2003 for the treatment of PD patients.